Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2014

Open Access 01-12-2014 | Research

Associations of retinol-binding protein 4 with oxidative stress, inflammatory markers, and metabolic syndrome in a middle-aged and elderly Chinese population

Authors: Yan Liu, Duan Wang, Di Li, Ruifang Sun, Min Xia

Published in: Diabetology & Metabolic Syndrome | Issue 1/2014

Login to get access

Abstract

Background

Retinol-binding protein 4 (RBP4), a novel adipokine secreted by adipocytes and the liver, has elevated levels in type 2 diabetes mellitus (T2DM). However, its association with human metabolic diseases remains controversial. The present study was designed to investigate the associations of plasma RBP4 levels with oxidative stress, inflammatory markers, and metabolic syndrome (MetS) in a Chinese population.

Method

We evaluated plasma RBP4 levels in a cross-sectional sample of 1748 Chinese men and women aged 50 to 70 years in Guangzhou using an in-house developed and validated sandwich ELISA. Plasma glucose, insulin, lipid profile, serum adiponectin, adipocyte fatty acid-binding protein (A-FABP), 8-iso-prostaglandin F2α (8-iso PGF2α), 13-(S)-hydroxyoctadecadienoic acid (13-HODE), high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL6), monocyte chemotactic protein 1 (MCP1) and tumor necrosis factor α (TNFα) were all measured. MetS was defined according to the updated National Cholesterol Education Program Adult Treatment Panel III criteria for Asian Americans.

Results

Circulating RBP4 levels were positively correlated with A-FABP (r = 0.104, P < 0.001), 8-iso PGF2α (0.236, P < 0.001), and 13-HODE (0.204, P < 0.001) and were inversely correlated with HDL cholesterol (r = −0.072, P = 0.004). After multivariable adjustment, the RBP4 levels were strongly associated with MetS and its components. The ORs (95% CIs) for the comparisons of the extreme quartiles of RBP4 were 3.46 (2.87, 4.42) for MetS, 5.92 (4.47, 8.02) for hypertriglyceridemia, 1.42 (1.11, 1.68) for reduced HDL cholesterol, 1.87 (1.48, 2.36) for central obesity and 2.74 (2.15, 3.36) for hyperglycemia (all P < 0.001). When we further controlled for adipokines, markers of oxidative stress and proinflammatory response, the association of RBP4 with central obesity was abolished but not the association with other MetS components.

Conclusions

Plasma RBP4 levels are associated with an adverse profile of oxidative stress and inflammatory markers and an increased risk of MetS in this Chinese population. These associations are independent of conventional risk factors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002, 287: 356-359. 10.1001/jama.287.3.356.CrossRefPubMed Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002, 287: 356-359. 10.1001/jama.287.3.356.CrossRefPubMed
2.
go back to reference Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.CrossRef Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.CrossRef
3.
go back to reference Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet. 2005, 365: 1415-1428. 10.1016/S0140-6736(05)66378-7.CrossRefPubMed Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet. 2005, 365: 1415-1428. 10.1016/S0140-6736(05)66378-7.CrossRefPubMed
4.
go back to reference Hee Park K, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE, Tsoukas MA, Geladari EV, Huh JY, Dincer F, Davis CR, Crowell JA, Mantzoros CS: Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013, 98: 4899-4907. 10.1210/jc.2013-2373.PubMedCentralCrossRef Hee Park K, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE, Tsoukas MA, Geladari EV, Huh JY, Dincer F, Davis CR, Crowell JA, Mantzoros CS: Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013, 98: 4899-4907. 10.1210/jc.2013-2373.PubMedCentralCrossRef
5.
go back to reference Maury E, Noël L, Detry R, Brichard SM: In vitro hyperresponsiveness to tumor necrosis factor-alpha contributes to adipokine dysregulation in omental adipocytes of obese subjects. J Clin Endocrinol Metab. 2009, 94: 1393-1400. 10.1210/jc.2008-2196.CrossRefPubMed Maury E, Noël L, Detry R, Brichard SM: In vitro hyperresponsiveness to tumor necrosis factor-alpha contributes to adipokine dysregulation in omental adipocytes of obese subjects. J Clin Endocrinol Metab. 2009, 94: 1393-1400. 10.1210/jc.2008-2196.CrossRefPubMed
6.
go back to reference Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean MEJ, Haffner SM: Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002, 25: 2016-2021. 10.2337/diacare.25.11.2016.CrossRefPubMed Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean MEJ, Haffner SM: Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002, 25: 2016-2021. 10.2337/diacare.25.11.2016.CrossRefPubMed
7.
go back to reference Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004, 114: 1752-1761. 10.1172/JCI21625.PubMedCentralCrossRefPubMed Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004, 114: 1752-1761. 10.1172/JCI21625.PubMedCentralCrossRefPubMed
8.
go back to reference Blaner WS: Retinol-binding protein: the serum transport protein for vitamin A. Endocr Rev. 1989, 10: 308-316. 10.1210/edrv-10-3-308.CrossRefPubMed Blaner WS: Retinol-binding protein: the serum transport protein for vitamin A. Endocr Rev. 1989, 10: 308-316. 10.1210/edrv-10-3-308.CrossRefPubMed
9.
go back to reference Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006, 354: 2552-2563. 10.1056/NEJMoa054862.CrossRefPubMed Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006, 354: 2552-2563. 10.1056/NEJMoa054862.CrossRefPubMed
10.
go back to reference Norseen J, Hosooka T, Hammarstedt A, Yore MM, Kant S, Aryal P, Kiernan UA, Phillips DA, Maruyama H, Kraus BJ, Usheva A, Davis RJ, Smith U, Kahn BB: Retinol-binding protein 4 inhibits insulin signaling in adipocytes by inducing proinflammatory cytokines in macrophages through a c-Jun N-terminal kinase- and toll-like receptor 4-dependent and retinol-independent mechanism. Mol Cell Biol. 2012, 32: 2010-2019. 10.1128/MCB.06193-11.PubMedCentralCrossRefPubMed Norseen J, Hosooka T, Hammarstedt A, Yore MM, Kant S, Aryal P, Kiernan UA, Phillips DA, Maruyama H, Kraus BJ, Usheva A, Davis RJ, Smith U, Kahn BB: Retinol-binding protein 4 inhibits insulin signaling in adipocytes by inducing proinflammatory cytokines in macrophages through a c-Jun N-terminal kinase- and toll-like receptor 4-dependent and retinol-independent mechanism. Mol Cell Biol. 2012, 32: 2010-2019. 10.1128/MCB.06193-11.PubMedCentralCrossRefPubMed
11.
go back to reference Klöting N, Graham TE, Berndt J, Kralisch S, Kovacs P, Wason CJ, Fasshauer M, Schön MR, Stumvoll M, Blüher M, Kahn BB: Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 2007, 6: 79-87. 10.1016/j.cmet.2007.06.002.CrossRefPubMed Klöting N, Graham TE, Berndt J, Kralisch S, Kovacs P, Wason CJ, Fasshauer M, Schön MR, Stumvoll M, Blüher M, Kahn BB: Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 2007, 6: 79-87. 10.1016/j.cmet.2007.06.002.CrossRefPubMed
12.
go back to reference Tschoner A, Sturm W, Engl J, Kaser S, Laimer M, Laimer E, Weiss H, Patsch JR, Ebenbichler CF: Retinol-binding protein 4, visceral fat, and the metabolic syndrome: effects of weight loss. Obesity (Silver Spring). 2008, 16: 2439-2444. 10.1038/oby.2008.391.CrossRef Tschoner A, Sturm W, Engl J, Kaser S, Laimer M, Laimer E, Weiss H, Patsch JR, Ebenbichler CF: Retinol-binding protein 4, visceral fat, and the metabolic syndrome: effects of weight loss. Obesity (Silver Spring). 2008, 16: 2439-2444. 10.1038/oby.2008.391.CrossRef
13.
go back to reference Ng TW, Watts GF, Barrett PH, Rye KA, Chan DC: Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care. 2007, 30: 2945-2950. 10.2337/dc07-0768.CrossRefPubMed Ng TW, Watts GF, Barrett PH, Rye KA, Chan DC: Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care. 2007, 30: 2945-2950. 10.2337/dc07-0768.CrossRefPubMed
14.
go back to reference Ingelsson E, Sundström J, Melhus H, Michaëlsson K, Berne C, Vasan RS, Risérus U, Blomhoff R, Lind L, Arnlöv J: Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Atherosclerosis. 2009, 206: 239-244. 10.1016/j.atherosclerosis.2009.02.029.CrossRefPubMed Ingelsson E, Sundström J, Melhus H, Michaëlsson K, Berne C, Vasan RS, Risérus U, Blomhoff R, Lind L, Arnlöv J: Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Atherosclerosis. 2009, 206: 239-244. 10.1016/j.atherosclerosis.2009.02.029.CrossRefPubMed
15.
go back to reference Sun Q, Kiernan UA, Shi L, Phillips DA, Kahn BB, Hu FB, Manson JE, Albert CM, Rexrode KM: Plasma retinol-binding protein 4 (RBP4) levels and risk of coronary heart disease: a prospective analysis among women in the nurses’ health study. Circulation. 2013, 127: 1938-1947. 10.1161/CIRCULATIONAHA.113.002073.PubMedCentralCrossRefPubMed Sun Q, Kiernan UA, Shi L, Phillips DA, Kahn BB, Hu FB, Manson JE, Albert CM, Rexrode KM: Plasma retinol-binding protein 4 (RBP4) levels and risk of coronary heart disease: a prospective analysis among women in the nurses’ health study. Circulation. 2013, 127: 1938-1947. 10.1161/CIRCULATIONAHA.113.002073.PubMedCentralCrossRefPubMed
16.
go back to reference Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS: Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2006, 29: 2457-2461. 10.2337/dc06-0360.CrossRefPubMed Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS: Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2006, 29: 2457-2461. 10.2337/dc06-0360.CrossRefPubMed
17.
go back to reference Chavez AO, Coletta DK, Kamath S, Cromack DT, Monroy A, Folli F, DeFronzo RA, Tripathy D: Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans. Am J Physiol Endocrinol Metab. 2009, 296: E758-E764. 10.1152/ajpendo.90737.2008.CrossRefPubMed Chavez AO, Coletta DK, Kamath S, Cromack DT, Monroy A, Folli F, DeFronzo RA, Tripathy D: Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans. Am J Physiol Endocrinol Metab. 2009, 296: E758-E764. 10.1152/ajpendo.90737.2008.CrossRefPubMed
18.
go back to reference Kotnik P, Fischer-Posovszky P, Wabitsch M: RBP4—a controversial adipokine. Eur J Endocrinol. 2011, 165: 703-711. 10.1530/EJE-11-0431.CrossRefPubMed Kotnik P, Fischer-Posovszky P, Wabitsch M: RBP4—a controversial adipokine. Eur J Endocrinol. 2011, 165: 703-711. 10.1530/EJE-11-0431.CrossRefPubMed
19.
go back to reference Promintzer M, Krebs M, Todoric J, Luger A, Bischof MG, Nowotny P, Wagner O, Esterbauer H, Anderwald C: Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor. J Clin Endocrinol Metab. 2007, 92: 4306-4343. 10.1210/jc.2006-2522. sss12CrossRefPubMed Promintzer M, Krebs M, Todoric J, Luger A, Bischof MG, Nowotny P, Wagner O, Esterbauer H, Anderwald C: Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor. J Clin Endocrinol Metab. 2007, 92: 4306-4343. 10.1210/jc.2006-2522. sss12CrossRefPubMed
20.
go back to reference Graham TE, Wason CJ, Bluher M, Kahn BB: Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects. Diabetologia. 2007, 50: 814-823. 10.1007/s00125-006-0557-0.CrossRefPubMed Graham TE, Wason CJ, Bluher M, Kahn BB: Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects. Diabetologia. 2007, 50: 814-823. 10.1007/s00125-006-0557-0.CrossRefPubMed
21.
go back to reference Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499-502.PubMed Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499-502.PubMed
22.
go back to reference Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005, 112: 2735-2752. 10.1161/CIRCULATIONAHA.105.169404.CrossRefPubMed Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005, 112: 2735-2752. 10.1161/CIRCULATIONAHA.105.169404.CrossRefPubMed
23.
go back to reference Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005, 436: 356-362. 10.1038/nature03711.CrossRefPubMed Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005, 436: 356-362. 10.1038/nature03711.CrossRefPubMed
24.
go back to reference Xia M, Liu Y, Guo H, Wang D, Wang Y, Ling W: Retinol binding protein 4 stimulates hepatic sterol regulatory element-binding protein 1 and increases lipogenesis through the peroxisome proliferator-activated receptor-γ coactivator 1β-dependent pathway. Hepatology. 2013, 58: 564-575.CrossRefPubMed Xia M, Liu Y, Guo H, Wang D, Wang Y, Ling W: Retinol binding protein 4 stimulates hepatic sterol regulatory element-binding protein 1 and increases lipogenesis through the peroxisome proliferator-activated receptor-γ coactivator 1β-dependent pathway. Hepatology. 2013, 58: 564-575.CrossRefPubMed
25.
go back to reference Qi Q, Yu Z, Ye X, Zhao F, Huang P, Hu FB, Franco OH, Wang J, Li H, Liu Y, Lin X: Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab. 2007, 92: 4827-4834. 10.1210/jc.2007-1219.CrossRefPubMed Qi Q, Yu Z, Ye X, Zhao F, Huang P, Hu FB, Franco OH, Wang J, Li H, Liu Y, Lin X: Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab. 2007, 92: 4827-4834. 10.1210/jc.2007-1219.CrossRefPubMed
26.
go back to reference Hammarstedt A, Graham TE, Kahn BB: Adipose tissue dysregulation and reduced insulin sensitivity in non-obese individuals with enlarged abdominal adipose cells. Diabetol Metab Syndr. 2012, 4: 42-10.1186/1758-5996-4-42.PubMedCentralCrossRefPubMed Hammarstedt A, Graham TE, Kahn BB: Adipose tissue dysregulation and reduced insulin sensitivity in non-obese individuals with enlarged abdominal adipose cells. Diabetol Metab Syndr. 2012, 4: 42-10.1186/1758-5996-4-42.PubMedCentralCrossRefPubMed
27.
go back to reference Takashima N, Tomoike H, Iwai N: Retinol-binding protessin 4 and insulin resistance. N Engl J Med. 2006, 355: 1392-author reply 1394–139s5CrossRefPubMed Takashima N, Tomoike H, Iwai N: Retinol-binding protessin 4 and insulin resistance. N Engl J Med. 2006, 355: 1392-author reply 1394–139s5CrossRefPubMed
28.
go back to reference Janke J, Engeli S, Boschmann M, Adams F, Böhnke J, Luft FC, Sharma AM, Jordan J: Retinol-binding protein 4 in human obesity. Diabetes. 2006, 55: 2805-2810. 10.2337/db06-0616.CrossRefPubMed Janke J, Engeli S, Boschmann M, Adams F, Böhnke J, Luft FC, Sharma AM, Jordan J: Retinol-binding protein 4 in human obesity. Diabetes. 2006, 55: 2805-2810. 10.2337/db06-0616.CrossRefPubMed
29.
go back to reference Matsuzawa Y, Funahashi T, Kihara S, Shimomura I: Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004, 24: 29-33. 10.1161/01.ATV.0000099786.99623.EF.CrossRefPubMed Matsuzawa Y, Funahashi T, Kihara S, Shimomura I: Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004, 24: 29-33. 10.1161/01.ATV.0000099786.99623.EF.CrossRefPubMed
30.
go back to reference Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS: Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation. 2007, 115: 1537-1543. 10.1161/CIRCULATIONAHA.106.647503.CrossRefPubMed Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS: Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation. 2007, 115: 1537-1543. 10.1161/CIRCULATIONAHA.106.647503.CrossRefPubMed
31.
go back to reference Ye X, Yu Z, Li H, Franco OH, Liu Y, Lin X: Distributions of C-reactive protein and its association with metabolic syndrome in middle-aged and older Chinese people. J Am Coll Cardiol. 2007, 49: 1798-1805. 10.1016/j.jacc.2007.01.065.CrossRefPubMed Ye X, Yu Z, Li H, Franco OH, Liu Y, Lin X: Distributions of C-reactive protein and its association with metabolic syndrome in middle-aged and older Chinese people. J Am Coll Cardiol. 2007, 49: 1798-1805. 10.1016/j.jacc.2007.01.065.CrossRefPubMed
32.
go back to reference Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D: Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab. 2007, 92: 1971-1974. 10.1210/jc.2006-2712.CrossRefPubMed Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D: Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab. 2007, 92: 1971-1974. 10.1210/jc.2006-2712.CrossRefPubMed
33.
go back to reference Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T: Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab. 2007, 92: 2712-2719. 10.1210/jc.2006-1249.CrossRefPubMed Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T: Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab. 2007, 92: 2712-2719. 10.1210/jc.2006-1249.CrossRefPubMed
34.
go back to reference Sell H, Habich C, Eckel J: Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol. 2012, 8: 709-716. 10.1038/nrendo.2012.114.CrossRefPubMed Sell H, Habich C, Eckel J: Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol. 2012, 8: 709-716. 10.1038/nrendo.2012.114.CrossRefPubMed
35.
go back to reference Romeo GR, Lee J, Shoelson SE: Metabolic syndrome, insulin resistance, and roles of inflammation–mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol. 2012, 32: 1771-1776. 10.1161/ATVBAHA.111.241869.CrossRefPubMed Romeo GR, Lee J, Shoelson SE: Metabolic syndrome, insulin resistance, and roles of inflammation–mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol. 2012, 32: 1771-1776. 10.1161/ATVBAHA.111.241869.CrossRefPubMed
36.
go back to reference Elnakish MT, Hassanain HH, Janssen PM, Angelos MG, Khan M: Emerging role of oxidative stress in metabolic syndrome and cardiovascular diseases: important role of Rac/NADPH oxidase. J Pathol. 2013, 231: 290-300.CrossRefPubMed Elnakish MT, Hassanain HH, Janssen PM, Angelos MG, Khan M: Emerging role of oxidative stress in metabolic syndrome and cardiovascular diseases: important role of Rac/NADPH oxidase. J Pathol. 2013, 231: 290-300.CrossRefPubMed
37.
go back to reference Pratico D: F(2)-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis. 1999, 147: 1-10. 10.1016/S0021-9150(99)00257-9.CrossRefPubMed Pratico D: F(2)-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis. 1999, 147: 1-10. 10.1016/S0021-9150(99)00257-9.CrossRefPubMed
38.
go back to reference Vangaveti V, Baune BT, Kennedy RL: Hydroxyoctadecadienoic acids: novel regulators of macrophage differentiation and atherogenesis. Ther Adv Endocrinol Metab. 2010, 1: 51-60. 10.1177/2042018810375656.PubMedCentralCrossRefPubMed Vangaveti V, Baune BT, Kennedy RL: Hydroxyoctadecadienoic acids: novel regulators of macrophage differentiation and atherogenesis. Ther Adv Endocrinol Metab. 2010, 1: 51-60. 10.1177/2042018810375656.PubMedCentralCrossRefPubMed
Metadata
Title
Associations of retinol-binding protein 4 with oxidative stress, inflammatory markers, and metabolic syndrome in a middle-aged and elderly Chinese population
Authors
Yan Liu
Duan Wang
Di Li
Ruifang Sun
Min Xia
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2014
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-6-25

Other articles of this Issue 1/2014

Diabetology & Metabolic Syndrome 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.